Sorafenib In The Treament Of Advanced Renal Cell Carcinoma (Analyses Of 22 Cases)

Objective: To investigate the efficacy and toxicity of Sorafenib in the treatment of advanced RCC in our department. Methods: From May 2007 to Oct 2007, 22 patients with advanced renal cell carcinoma were given oral sorafenib 400 mg twice daily. The pathological diagnoses of primary tumors were clear cell carcinoma in all 22 patients. The metastatic sites of all the patients included 14 in lungs, 4 in liver, 7 in bone, 1 in adrenal gland, 4 in retroperitoneal nodes. Results: 1(4.5%) patients achieved CR, 4(18.2%) patients achieved PR, 17(77.3% ) patients achieved SD. PD has not been observed in our group. Common toxicity were hand-foot skin reaction, alopecia, oral ulcer and hypertension. Conclusions: Sorafenib was effective in controlling tumor growth and its toxicity was relatively minor as compared to that of other systemic chemotherapy and most patient expressed nice tolerance.